(Total Views: 496)
Posted On: 09/18/2020 4:51:46 AM
Post# of 148899
“Richard Trauger, who formerly served as CytoDyn’s chief science officer and led the effort to acquire leronlimab, left the company in 2013. “
There’s a poster on ihub ,3x, with an agenda who speaks of prior relationships to the company with an agenda to remove Nader.
The trials were going no where before Nader brought in Amarex. They even wrote a white paper about their rescue process of our trials.
There’s a poster on ihub ,3x, with an agenda who speaks of prior relationships to the company with an agenda to remove Nader.
The trials were going no where before Nader brought in Amarex. They even wrote a white paper about their rescue process of our trials.
(2)
(0)Scroll down for more posts ▼
